Zoetis Stock Declines Amid Controversy Over Pain Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy ZTS?
Source: NASDAQ.COM
Zoetis Inc's stock has declined by 3.00% and has hit a 52-week low amid ongoing controversy surrounding its osteoarthritis pain treatment, Librela. The company faces backlash due to a 16% decline in Librela sales in 2025 attributed to adverse side effects, which has negatively impacted its brand image. Despite a dismissed class action lawsuit, the controversy raises concerns about future sales performance. However, Zoetis achieved a 2% increase in total sales in 2025, showcasing its business resilience and diversification, with a strong drug pipeline expected to enhance growth prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZTS
Wall Street analysts forecast ZTS stock price to rise
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 114.970
Low
130.00
Averages
154.20
High
200.00
Current: 114.970
Low
130.00
Averages
154.20
High
200.00
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including vaccines, anti-infectives, parasiticides, dermatology, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zoetis Stock Declines Amid Controversy Over Pain Treatment
- Drug Controversy Impact: Zoetis faces backlash over its osteoarthritis pain treatment Librela, which has led to a 16% decline in sales in 2025 due to adverse side effects, negatively impacting the company's brand image, although a class action lawsuit was dismissed.
- Sales Growth Potential: Despite the challenges with Librela, Zoetis achieved a 2% increase in total sales in 2025, demonstrating the resilience and diversification of its business, with the entire osteoarthritis product line generating $568 million in sales, accounting for 6% of total revenue.
- Strong Drug Pipeline: Zoetis expects to receive regulatory approvals for potential drugs in major markets over the next few years, with 12 candidates projected to generate at least $100 million in annual sales, enhancing the company's growth outlook.
- Market Demand Drivers: With rising spending on pets among younger generations and increasing demand for animal proteins in emerging markets, Zoetis is poised to benefit from long-term market trends, with analysts forecasting an average annual earnings growth of 9.3% over the next three to five years.
See More
Zoetis Stock's Low Valuation Presents Investment Opportunity
- Valuation Drop: Zoetis stock currently trades at a price-to-earnings ratio of just 19, marking its lowest valuation since going public, significantly down from an average of 39 over the past decade, indicating market concerns about future growth and presenting a potential buying opportunity for investors.
- Librela Controversy: The company has faced backlash over side effects from its osteoarthritis treatment for dogs, Librela, leading to a 16% decline in sales in 2025; although a class action lawsuit was dismissed, the damage to brand reputation may impact future sales performance.
- Stable Sales Growth: Despite the challenges with Librela, Zoetis achieved a 2% overall sales growth in 2025, demonstrating its business diversification and resilience, with expectations that 12 potential drugs could generate at least $100 million in annual sales in the coming years.
- Optimistic Market Outlook: With young people increasingly spending on pets and rising demand for animal proteins in emerging markets, Zoetis anticipates an average earnings growth of 9.3% annually over the next three to five years, providing a strong rationale for investing in its stock at this low valuation.
See More
Analysis of Investment Prospects in Healthcare Stocks
- Animal Health Leader: Zoetis has faced challenges over the past two years, including increased competition and scrutiny over drug side effects; however, its strong market position and the potential market for untreated dogs make it attractive for long-term investors, with expectations to continue launching new products to meet rising pet spending.
- New Drug Development Potential: BioNTech has underperformed in the coronavirus vaccine market, but its impressive pipeline with over 25 clinical trials in oncology, particularly the promising BNT327 developed with Bristol Myers Squibb, could set new standards of care across multiple indications, with significant clinical and regulatory progress expected over the next five years.
- Gene Editing Risks: Intellia Therapeutics' lonvo-z and nex-z are undergoing phase 3 studies but face uncertainty; despite the FDA lifting the hold on clinical trials, the high costs and complexities of gene editing treatments make steady revenue generation unlikely in the coming years, presenting substantial investment risks.
- Dividend Appeal: Zoetis has increased its dividends by 458% over the past decade, making it a top choice for income-seeking investors, reflecting its long-term investment value in the animal health market despite facing short-term challenges.
See More
Latest Rating Changes on Wall Street
- Apple's Positive Outlook: Wells Fargo reiterates Apple (AAPL) as overweight, anticipating better-than-expected iPhone demand and continued double-digit growth in services ahead of its earnings report, with a price target of $300.
- SolarEdge Downgraded: Goldman Sachs downgrades SolarEdge (SEDG) from neutral to sell, citing elevated expectations and challenging valuation as key factors behind the downgrade.
- Meta's Advertising Growth: Deutsche Bank maintains a buy rating on Meta (META), highlighting that its investments in AI are yielding increasing returns for advertisers, which supports accelerated advertising revenue growth.
- Autodesk Positioned Well: Jefferies initiates coverage on Autodesk (ADSK) with a buy rating, noting its strong positioning in agentic AI and solid fundamentals, presenting an attractive risk/reward profile at current levels.
See More
Zoetis Earnings Outlook Shows Optimism Ahead
- Stock Performance: Zoetis (ZTS) fell 1.78% to $117.86 in the latest trading session, underperforming the S&P 500's 0.11% decline, indicating market caution regarding its short-term outlook.
- Earnings Expectations: The company is set to report an EPS of $1.61 on May 7, 2026, representing an 8.78% increase year-over-year, with revenue projected at $2.31 billion, reflecting a 4.02% growth, showcasing its sustained growth potential in the animal health sector.
- Analyst Ratings: Currently holding a Zacks Rank of #3 (Hold), Zoetis has seen a 0.05% increase in EPS estimates over the past 30 days, suggesting investor optimism about its future performance, which could positively influence its stock price.
- Valuation Analysis: With a forward P/E ratio of 17.14, Zoetis aligns with the industry average, while its PEG ratio of 1.84 indicates reasonable valuation in terms of expected earnings growth, reflecting its competitive position within the medical drugs industry.
See More
Zoetis (ZTS) Q2 2025 Earnings Call Transcript
See More
Zoetis Stock Declines Amid Controversy Over Pain Treatment
- Drug Controversy Impact: Zoetis faces backlash over its osteoarthritis pain treatment Librela, which has led to a 16% decline in sales in 2025 due to adverse side effects, negatively impacting the company's brand image, although a class action lawsuit was dismissed.
- Sales Growth Potential: Despite the challenges with Librela, Zoetis achieved a 2% increase in total sales in 2025, demonstrating the resilience and diversification of its business, with the entire osteoarthritis product line generating $568 million in sales, accounting for 6% of total revenue.
- Strong Drug Pipeline: Zoetis expects to receive regulatory approvals for potential drugs in major markets over the next few years, with 12 candidates projected to generate at least $100 million in annual sales, enhancing the company's growth outlook.
- Market Demand Drivers: With rising spending on pets among younger generations and increasing demand for animal proteins in emerging markets, Zoetis is poised to benefit from long-term market trends, with analysts forecasting an average annual earnings growth of 9.3% over the next three to five years.
See More
Zoetis Stock's Low Valuation Presents Investment Opportunity
- Valuation Drop: Zoetis stock currently trades at a price-to-earnings ratio of just 19, marking its lowest valuation since going public, significantly down from an average of 39 over the past decade, indicating market concerns about future growth and presenting a potential buying opportunity for investors.
- Librela Controversy: The company has faced backlash over side effects from its osteoarthritis treatment for dogs, Librela, leading to a 16% decline in sales in 2025; although a class action lawsuit was dismissed, the damage to brand reputation may impact future sales performance.
- Stable Sales Growth: Despite the challenges with Librela, Zoetis achieved a 2% overall sales growth in 2025, demonstrating its business diversification and resilience, with expectations that 12 potential drugs could generate at least $100 million in annual sales in the coming years.
- Optimistic Market Outlook: With young people increasingly spending on pets and rising demand for animal proteins in emerging markets, Zoetis anticipates an average earnings growth of 9.3% annually over the next three to five years, providing a strong rationale for investing in its stock at this low valuation.
See More
Analysis of Investment Prospects in Healthcare Stocks
- Animal Health Leader: Zoetis has faced challenges over the past two years, including increased competition and scrutiny over drug side effects; however, its strong market position and the potential market for untreated dogs make it attractive for long-term investors, with expectations to continue launching new products to meet rising pet spending.
- New Drug Development Potential: BioNTech has underperformed in the coronavirus vaccine market, but its impressive pipeline with over 25 clinical trials in oncology, particularly the promising BNT327 developed with Bristol Myers Squibb, could set new standards of care across multiple indications, with significant clinical and regulatory progress expected over the next five years.
- Gene Editing Risks: Intellia Therapeutics' lonvo-z and nex-z are undergoing phase 3 studies but face uncertainty; despite the FDA lifting the hold on clinical trials, the high costs and complexities of gene editing treatments make steady revenue generation unlikely in the coming years, presenting substantial investment risks.
- Dividend Appeal: Zoetis has increased its dividends by 458% over the past decade, making it a top choice for income-seeking investors, reflecting its long-term investment value in the animal health market despite facing short-term challenges.
See More
Latest Rating Changes on Wall Street
- Apple's Positive Outlook: Wells Fargo reiterates Apple (AAPL) as overweight, anticipating better-than-expected iPhone demand and continued double-digit growth in services ahead of its earnings report, with a price target of $300.
- SolarEdge Downgraded: Goldman Sachs downgrades SolarEdge (SEDG) from neutral to sell, citing elevated expectations and challenging valuation as key factors behind the downgrade.
- Meta's Advertising Growth: Deutsche Bank maintains a buy rating on Meta (META), highlighting that its investments in AI are yielding increasing returns for advertisers, which supports accelerated advertising revenue growth.
- Autodesk Positioned Well: Jefferies initiates coverage on Autodesk (ADSK) with a buy rating, noting its strong positioning in agentic AI and solid fundamentals, presenting an attractive risk/reward profile at current levels.
See More
Zoetis Earnings Outlook Shows Optimism Ahead
- Stock Performance: Zoetis (ZTS) fell 1.78% to $117.86 in the latest trading session, underperforming the S&P 500's 0.11% decline, indicating market caution regarding its short-term outlook.
- Earnings Expectations: The company is set to report an EPS of $1.61 on May 7, 2026, representing an 8.78% increase year-over-year, with revenue projected at $2.31 billion, reflecting a 4.02% growth, showcasing its sustained growth potential in the animal health sector.
- Analyst Ratings: Currently holding a Zacks Rank of #3 (Hold), Zoetis has seen a 0.05% increase in EPS estimates over the past 30 days, suggesting investor optimism about its future performance, which could positively influence its stock price.
- Valuation Analysis: With a forward P/E ratio of 17.14, Zoetis aligns with the industry average, while its PEG ratio of 1.84 indicates reasonable valuation in terms of expected earnings growth, reflecting its competitive position within the medical drugs industry.
See More
Zoetis (ZTS) Q2 2025 Earnings Call Transcript
See More
